MedTrace Logo

Phase I/II Study of Monoclonal Factor IX Concentrate for Factor IX Deficiency

NCT00004801 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2005-06-24

No results posted yet for this study

Summary

OBJECTIVES:

Assess the safety and long-term efficacy of monoclonal factor IX concentrate in patients with factor IX deficiency.

Conditions

  • Hemophilia B
  • Factor IX Deficiency

Interventions

DRUG

monoclonal factor IX replacement therapy

Sponsors & Collaborators

  • University of North Carolina

    collaborator OTHER

  • National Center for Research Resources (NCRR)

    lead NIH

Principal Investigators

  • Gilbert C. White · University of North Carolina

Study Design

Purpose
TREATMENT

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1992-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004801 on ClinicalTrials.gov